UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 18, 2014 

Registrant's telephone number, including area code:   (301) 961-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Item 1.01. Entry into a Material Definitive Agreement.

On August 18, 2014, Sucampo Pharmaceuticals, Inc. (the "Company") subsidiary, Sucampo AG, entered into an exclusive global manufacturing and supply agreement (the "EMSA") with R-Tech Ueno, Ltd. (the "R-Tech") for ten years with an automatic renewal of ten more years unless the parties terminate the EMSA. R-Tech shall provide to the Company and its subsidiaries clinical and commercial supply of lubiprostone, in certain circumstances, as API, intermediate or finished product globally at supply prices that are reduced from the current supply prices. The current manufacturing and supply agreements for lubiprostone are superseded by the EMSA; except that the EMSA will not apply to the clinical and commercial supply of lubiprostone to the United States and Canada until the Supply and Purchase Agreement among Takeda Pharmaceutical Company, Ltd., R-Tech and us has expired and to Japan until the expiration of the manufacturing and supply agreement for Japan or certain material circumstances occur. We also have the right to qualify a back-up supplier for lubiprostone in expanded situations, e.g. authorized generic, additional formulations, inability to supply in certain circumstances, and others. There are no commercial or development milestones in the EMSA and all other terms contained in the superseded manufacturing and supply agreements are generally contained in the EMSA. The EMSA is effective as of January 1, 2014, notwithstanding the date the Company signed the Agreement.

Item 1.02. Termination of a Material Definitive Agreement.

The information set forth under "Item 1.01. Entry into a Material Definitive Agreement" of this report relating to the superseding of the certain current manufacturing and supply agreements is hereby incorporated by reference in this Item 1.02.

Item 8.01. Other Events.

On August 21, 2014, the Company issued a press release pursuant to which it announced that it had entered into the EMSA. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.